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ABSTRACT
Genetic modification is critically enabling for studies
addressing specification and maintenance of cell fate;
however, methods for engineering modifications are
inefficient. We demonstrate a rapid and efficient recom-
bination system in which an inducible, floxed cre allele
replaces itself with an incoming transgene. We target
this inducible cassette exchange (ICE) allele to the
(HPRT) locus and demonstrate recombination in murine
embryonic stem cells (ESCs) and primary cells from
derivative ICE mice. Using lentivectors, we demonstrate
recombination at a randomly integrated ICE locus in
human ESCs. To illustrate the utility of this system, we
insert the myogenic regulator, Myf5, into the ICE locus
in each platform. This enables efficient directed differ-
entiation of mouse and human ESCs into skeletal muscle
and conditional myogenic transdetermination of pri-
mary cells cultured in vitro. This versatile tool is thus
well suited to gain-of-function studies probing gene
function in the specification and reprogramming of cell
fate. STEM CELLS 2011;29:1580–1588
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INTRODUCTION
The isolation of mouse embryonic stem cells (mESCs) and
human ESCs (hESCs) from blastocyst embryos [1–3] has
enabled the modeling of early embryonic developmental
events and new strategies for tissue engineering. Many stud-
ies, especially those probing specification and maintenance of
cell fate and mechanisms of differentiation, require genetic
modification and would be facilitated by robust methods to
modify cells for conditional gene expression. Because every
locus differs in its own unique expressability, particularly the
differential level of openness or extent to which it is subject
to silencing within different lineages, there are obvious advan-
tages to targeting a known and defined locus, especially when
comparing the effects of expressing two different genes. Ho-
mologous recombination, commonly performed in mESCs [4,
5] is very difficult to implement in other cell types including
hESCs [6], and although routine in the murine system, suffers
from low frequencies (106) of recombination and compara-
tively high frequencies of random integration. Chimeric zinc
finger nucleases [7] dramatically improve rates of homologous
recombination but the exposure of the genome to such nucle-
ases may result in off-target mutations [8]. Here we describe
a system that enables high-efficiency cassette-exchange
replacement of a doxycycline-inducible floxed cre transgene
with a new transgene of interest. The system, referred to as
inducible cassette exchange (ICE), enables high efficiency
integration of genes of interest into cells bearing a single-
copy ICE locus. We have created platforms for this recombi-
nation system in mESCs, primary cells derived from ICE
mice, and hESCs and apply this tool to probe the acquisition
and stability of cell fate.
MATERIALS AND METHODS
Generation of A2Lox.cre mESCs
mESCs were cultured on irradiated mouse embryonic fibroblasts
(MEFs) in Dulbecco’s modified Eagle’s medium (DMEM)/15%
FBS, penicillin/streptomycin (P/S, Gibco), 2 mM glutamax (Invi-
trogen, Carlsbad, CA, http://www.invitrogen.com), nonessential
amino acids, 0.1 mM b-mercaptoethanol, and 100 U/mL leukemia
inhibitory factor (LIF) (Peprotech, Rocky Hill, NJ, http://
www.peprotech.com). For embryoid body (EB) differentiation,
ESCs were trypsinized and replated in differentiation medium
(IMDM/15% FBS, 200 lg/mL transferrin (Sigma, St. Louis, MO,
http://www.sigma-aldrich.com), 4.5 mM monothiolglycerol (Sigma),
50 lg/mL ascorbic acid (Sigma), and 2 mM glutamax) for 30
minutes to allow MEFs to adhere. Nonadherent cells (105) were
plated as a cell suspension in low adherence dishes on a slowly
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rotating shaker. To generate A2Lox.cre ESCs, the hypoxanthine-
guanine phosphoribosyltransferase (HPRT) 50 repair/targeting
plasmid [9] carrying the cassette exchange doxycycline (tetracy-
cline)-responsive promoter (TRE)-2loxP-Dneo inducible target
locus [10] was digested with XhoI and ligated to an XhoI–SalI
fragment bearing the cre transgene from pSalk-cre [11]. SalI-line-
arized DNA (20 lg) was electroporated into 6  106 A17
mESCs, and selection in ES medium with HAT supplement (Invi-
trogen) was initiated 24 hours later.
Generation of inducible GFP and iMyf5
mESC Lines
To generate derivative inducible mESC lines, A2Lox.cre mESC
lines were exposed to 500 ng/mL doxycycline for 24 hours, tryp-
sinized, counted, and 2  105 cells were electroporated (Amaxa,
Ko¨ln, Germany, http://www.lonzabio.com nucleofector 96-well shut-
tle, solution VHPH-1001, waveform program 96-CG-104) with 4 lg
of p2Lox-mMyf5 or p2Lox-EGFP plasmid and plated on neo-MEFs
(Specialty Media, St. Louis, MO, http://www.sigma-aldrich.com).
Selection was initiated in 300 lg/mL G418 (Gibco, Carlsbad, CA,
http://www.invitrogen.com) 24 hours after plating and maintained
for 10 days. Colonies were picked at day 8 and replated on neo-
MEFs for expansion.
For myogenic differentiation, iMyf5 mESCs were differenti-
ated as EBs for 2 days, then attached to gelatin-coated plates in
EB differentiation medium. In the initial 4 days, cells were cul-
tured in DMEM/10% FBS with 500 ng/mL doxycyline. They were
then switched to DMEM/2% horse serum (HS) with 500 ng/mL
doxycyline and cultured for an additional 4 days.
Generation of iDsRed2 and iMyf5 Kidney Cell Lines
ICE mice were derived at the University of Texas UT South-
western Transgenic Core Facility by blastocyst injection of ZX1
mESCs, an ICE mESC line related to A2Lox.cre but with an
improved TRE promoter [12]. Mice were housed in a pathogen-
free environment and cared for under the guidance of the Univer-
sity of Texas UT Southwestern and University of Minnesota
Institutional Animal Care and Use Committees. Primary kidney
cells were obtained from collagenase I-treated, miced whole kid-
ney pieces from male ICE mice. These were allowed to attach in
DMEM/10% FBS and P/S at 37C, enabling constituent cells to
spread over the surface of a T75 flask. Cells were then passaged
by trypsinization at 80% confluence. p2Lox-DsRed2 and -Myf5
were introduced by electroporation with an Amaxa nucleofector
96-well shuttle (Nucleofector II: VPI-1002 waveform program
U-012). For the quantification of recombination, cells were pas-
saged twice and induced overnight with 500 ng/mL doxycycline.
For the derivation of iMyf5 kidney cells, 2 days post-nucleofec-
tion, selection was initiated in 75 lg/mL G418 for 4 days, then
brought to 100 lg/mL, and maintained over a period of 20 days.
During selection, cells were passaged at 80% confluence. For
myogenic differentiation, iMyf5 primary kidney cells were
induced with 500 ng/mL doxycycline and cultured on gelatin-
coated plates in myogenic medium (DMEM/20% FBS, 10 ng/mL
basic fibroblast growth factor (bFGF), and 107 M dexametha-
sone) for 8 days. When the culture reached 100% confluency,
medium was replaced with DMEM/2% HS with 500 ng/mL dox-
ycycline for an additional 4 days.
Lentivirus Production
Lentiviral supernatant was produced in 293T cells cultured in
DMEM/10% FBS. Lentiviral plasmid constructs, packaging con-
struct pHR8.2deltaR, and envelop plasmid pCMV-VSV-G were
cotransfected using FUGENE HD (Roche, Basel, Switzerland,
www.roche-applied-science.com). Medium was changed after 24
hours and the viral supernatant was collected at 48 hours post-
transfection. Filtered supernatant (0.45 lm) was spiked with poly-
brene (4 lg/mL) and applied to cells plated at low density 1 day
before infection. Spin infection was performed at 2,000g at 33C
for 90 minutes in a Sorval Legend RT centrifuge. Cells were
incubated for an additional 3 hours at 37C/5% CO2 at which
time the supernatant was replaced with fresh medium.
Generation of A2Lox.cre.I hESCs
H9 hESCs were cultured in mTESR (Stemcell Technologies) sup-
plemented with P/S (Gibco) on growth factor-free matrigel (BD
Biosciences)-treated dishes and passaged using Accumax (Milli-
pore, Billerica, MA, www.millipore.com) with Rock inhibitor
(Enzo Life Sciences, Farmingdale, NY, http://www.enzolifesciences.
com). Cells were transduced twice with high titer supernatants of
Lenti-rtTA [13], a lentivector bearing rtTA under the ubiquitin C
promoter (a modified version of FUGW [14] in which rtTA2SM2
from pUHDrtTA2SM2 [15] was introduced downstream of the
Ubiquitin promoter) to generate derivative H9:rtTA hESCs. These
cells were then transduced with 2Lox.cre-ires-GFP [13] lentivec-
tor over a dilution series of supernatant. Cells were pulsed with
500 ng/mL doxycycline, and bulk sorted from a dilution with
<5% transduction, to bias for single-copy integration events.
Sorted cells were grown to 50% confluence, pulsed with doxycy-
cline, and sorted a second time to remove clones in which the
integration was silenced. When these cells reached 50% conflu-
ence, they were single cell sorted into 96-well dishes and clonal
cell lines were expanded. A split from each clonal cell line was
tested for levels of GFP inducibility, and the best clones were
tested for recombination. Clone H9-2Lox.cre.I was selected for
all following experiments.
Generation of H9imCherry and H9iMyf5 hESCs
H9-2Lox.cre.I cells were treated with 500 ng/mL doxycycline for
24 hours and harvested, and five batches of 2  105 cells were
nucleofected with 4 lg p2Lox-mCherry, 4 lg p2lox-DS-RED2,
or p2Lox-hMyf5-ires-mCherry with an Amaxa 96-well nucleofec-
tor shuttle using VHPH-5003 solution for H9 cells and the hESC
waveform protocol, 96-CB-150. For quantification of recombina-
tion, cells were passaged twice and then induced overnight with
500 ng/mL doxycycline. To generate imCherry or iMyf5 deriva-
tives, cells were expanded to 50% confluence on a T75 flask and
induced with 200 ng/mL doxycycline overnight. The following
day, red fluorescent cells were sorted and plated on a six-well
dish. Secondary and tertiary enrichment sorts were performed in
the same way.
Cells were differentiated by plating 4  105 cells per millili-
ter in low-adherence dishes in mTESR medium for 2 days to
allow aggregates to form. Medium was then changed to growth
factor-free mTESR (Stemcell Technologies, Vancouver, Canada,
www.stemcell.com) supplemented with 10 ng/mL human bone
morphogenetic protein 4 (hBMP4), 3 ng/mL hActivinA, and 10
ng/mL human basic fibroblast growth factor (hbFGF) (all from
Peprotech) for 4 days. BMP4 and ActivinA were then withdrawn
and bFGF was reduced to 5 ng/mL hbFGF for the next 4 days.
At this stage, EBs were plated in adherent dishes to allow attach-
ment in myoblast medium: DMEMF12 supplemented with 20%
FBS, P/S, 10 ng/mL hbFGF, 107 M dexamethasone, and 0.1
mM b-mercaptoethanol. After 2 days of attachment, adherent
cells, referred to hereafter as mesenchymal cells, were collected
by trypsinization and expanded for up to six passages. For myo-
genic differentiation, mesenchymal cells were maintained in dox-
ycycline from the point of attachment. Terminal differentiation
was induced by switching myoblast medium for DMEM/2% HS
for 6 days.
Immunofluorescence and Western Blotting
Cells were cultured on gelatin-coated coverslips, fixed with 4%
paraformaldehyde for 20 minutes, permeabilized by 0.3% Triton
X-100 for 30 minutes, and blocked by 10% goat serum for 1
hour at room temperature. Primary mouse anti-MyoD (BD Bio-
sciences c# 554130) or mouse anti-sarcomeric myosin (MF20,
Developmental Studies Hybridoma Bank, University of Iowa, IA,
dshb.biology.iowa.edu) was incubated in phosphate buffer saline
(PBS)/2% goat serum at 4C overnight, followed by secondary
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goat anti-mouse Cy3- or Alexa-555-conjugated antibodies (Sigma,
and Invitrogen, respectively) at room temperature for 45 minutes.
Cells were counterstained using 40,6-diamidino-2-phenylindole
(Invitrogen) to visualize nuclei and mounted in ‘‘Immu-Mount’’
(Thermo Scientific, Pittsburgh, PA, www.thermoscientific.com).
Images were acquired on an Axio Observer.Z1 microscope (Zeiss,
Oberkochen, Germany, www.zeiss.de). For Western Blotting,
cells were cultured on gelatin-coated plates, and protein was
extracted by using RIPA buffer. Primary mouse anti-GAPDH
(HRP conjugated) was used to detect the specific band of 36 kD.
Primary mouse anti-Myf5 (SC-302 clone C-20) and secondary
goat anti-rabbit-HRP conjugated were used to detect the Myf5
specific band at 35 kD. Primary mouse anti-MyoD (BD Bioscien-
ces c# 554130), mouse anti-myogenin (BD Bioscience, East
Rutherford, NJ, http://www.bd.com c# 556358), mouse anti-M-
cadherin (BD Bioscience c# 611100), mouse anti-myosin heavy
chain (MyHC [DSHB F1.652S]), and secondary anti-mouse HRP
conjugated were used to detect specific bands of 45, 34, 130, 180
kD, respectively.
Quantitative Real Time RT-PCR
Total RNA was extracted with Trizol (Invitrogen) and cDNA
was generated using 1 lg DNase-treated RNA with oligo-dT primers
and TermoScript (Invitrogen). PCR was performed using TaqMan
Real Time PCR premixtures on a 7500 RT-PCR System from Applied
Biosystems. For muscle-related genes, premade probes were
purchased from Applied Biosystems: Myod1 Mm00440387_m1,
Myf5 Mm00435125_m1, Myog Mm00446194_m1, Mck
Mm0432556_m1, Desmin Mm00802455_m1, m-Cad Mm00483183_m1,
and Gapdh Mm99999915_g1. For human probes: MYOD1
Hs00159528_m1, MYF5 Hs00271574_m1, MYOG Hs01072232_m1,
DESMIN Hs00157258_m1, and GAPDH Hs99999905-m1. All reac-
tions were performed at least in triplicate and the data were analyzed
by 7500 System Software (Applied Biosystems, Foster City, CA,
www.appliedbiosystems.com). The difference in threshold cycle num-
ber between transcripts of interest and GAPDH was used to determine
the abundance of transcript relative to GAPDH (D-CT method).
Statistical Analyses
All experiments were done at least three times. Data shown for
real time PCR are the mean 6 SD. Difference between means
was compared by the two-tailed Student’s t test (GraphPad Prism
five) and was considered significantly different at p < .05.
RESULTS
Generation of ICE mESCs
The genomic region upstream of HPRT has been demon-
strated to be a site at which transgenes express reliably [9,
16-18], presumably due to HPRT being a housekeeping gene,
active in all cell types and therefore embedded in constitu-
tively open chromatin. We have targeted this site with a dox-
ycycline-inducible cre transgene flanked by heterologous,
self-incompatible loxP sites (Fig. 1A) in A17 mESCs, a deriv-
ative of E14Tg2a [19] in which rtTA has been inserted into
the Rosa26 locus [20]. Downstream of the floxed cre is Dneo,
a G418 resistance gene lacking a start codon and promoter
[21]. These cells are referred to as A2Lox.cre. Treating cells
with doxycycline causes cre to be expressed, rendering the
cells competent for recombination. When transfected with
p2Lox, a plasmid bearing the same heterologous loxP sites, a
cassette exchange recombination replaces cre with a gene of
interest from the incoming plasmid. Because the orientation
of the loxP sites is inverted on the plasmid relative to the
chromosome, the plasmid in its entirety (except for the short
sequence between the loxP sites) is inserted. At the upstream
loxP site, a gene of interest is brought under the regulation of
the doxycycline-inducible promoter, while at the downstream
loxP site, a PGK promoter and a start codon are spliced in-
frame with the Dneo gene. This results in reversion to G418
resistance and selection for precise integration [21].
To measure the efficiency of ICE recombination in
mESCs, we treated A2Lox.cre cells with doxycycline for 24
hours to induce cre expression or kept untreated cells as con-
trols. We then nucleofected both with p2Lox bearing GFP.
After several days of growth in the absence of doxycycline,
cells from both arms were treated with doxycycline for 48
hours. In cells nucleofected with p2Lox-GFP but not previ-
ously exposed to doxycycline, no integrants were observed;
however, in cells previously pulsed with doxycycline to
induce cre, a recombinant population was observed and the
frequency of recombination was determined to be >1/1,000
(the frequency of GFPþ cells, Fig. 1B, 1C). This is approxi-
mately three orders of magnitude more efficient than homolo-
gous recombination. By subjecting the treated population to
G418 selection, individual colonies can be isolated, and these
now show inducible expression, both in the ESC stage, as
well as when differentiated for several days as EBs (Fig. 1D).
Directing Mesoderm Differentiation with
Myogenic Regulatory Factors
To evaluate the usefulness of this system in probing mecha-
nisms of cell fate determination, we sought to derive a devel-
opmental lineage that is poorly represented in conventional
mES in vitro differentiation. The skeletal myogenic lineage is
very difficult to derive from mESCs, most likely because of a
deficiency in the inductive signals that initiate somitogenesis
in paraxial mesoderm [22]. To test the ability of this inducible
system to direct the lineage choice of differentiating cells,
specifically to direct cells into the myogenic lineage, we gen-
erated a new inducible mESC line using this system: iMyf5
(for inducible Myf5). Myf5 and its related paralog MyoD dis-
play significant genetic redundancy in early myogenic devel-
opment [23]; however, Myf5 is temporally and genetically
upstream of MyoD [24, 25], thought to be directly induced by
Pax3 in cells of the hypaxial somite [26], and is downregu-
lated following myogenic specification. We differentiated
iMyf5 cells in serum suspension (EB) culture for 2 days, con-
ditions under which mesoderm is potently induced. EBs were
then allowed to attach, and doxycycline was applied from this
time point onward, to induce Myf5 expression in early meso-
dermal progenitors as soon as they emerged (Fig. 2A). In the
presence of Myf5 induction, cells with MyoDþ nuclei were
observed, indicating myogenic commitment, whereas in con-
trol cells lacking Myf5 induction, cells were uniformly MyoD-
negative (Fig. 2B). After 4 days of monolayer culture, cells
were exposed to myogenic differentiation medium (2% HS,
conditions that promote myotube formation from myoblasts)
for an additional 4 days. In the absence of Myf5 induction, no
cell fusion was observed and MyHC expression was absent;
however, in cells exposed to Myf5, large numbers of multi-
nucleated MyHCþ myotubes were formed (Fig. 2B). Differ-
entiated cells were evaluated for myogenic gene expression
by quantitative RT-PCR (qRT-PCR). As expected, Myf5 was
robustly expressed in doxycycline-treated cells, and cells
exposed to Myf5 for 8 days expressed the downstream myo-
genic regulatory factors, MyoD and Myogenin. In addition,
various structural gene markers of terminal myogenic devel-
opment were observed (Fig. 2C, 2D). These data demonstrate
the utility of the system for probing the activity of genes that
regulate early events in murine embryonic development, in
this case showing that Myf5 expression is sufficient to pro-
mote the myogenic commitment of nascent mesoderm and
establishing a novel and rapid method of differentiating
mESCs into skeletal muscle tissue.
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ICE Recombination in Human ESCs
To facilitate similar studies in a human system, we sought to
derive a hESC with an ICE target locus. We elected to
randomly integrate ICE loci and select clones with favorable
expression characteristics. We therefore used a modified
version of the ICE locus in which an ires-GFP reporter fol-
lows the Cre gene within the domain flanked by loxP sites
(Fig. 3A). The entire locus is carried by a lentiviral vector,
which allows for efficient introduction of the ICE locus. The
presence of the GFP reporter allows the isolation of clonal
cell lines that have picked up a genomic integration of the
cassette, and their evaluation to determine which have favor-
able doxycycline responsiveness. In addition, following cassette
exchange, recombinants can be distinguished from parental cells
by the absence of inducible GFP expression. We transduced H9
hESCs [1] with this construct at low titer to favor single-copy
integration, used a transient pulse of doxycycline to identify inte-
grants, which we sorted and replated. Following expansion of
this founder population, we pulsed with doxycycline a second
time and single cell sorted to isolate clonal cell lines. We eval-
uated clones for ICE recombination by nucleofecting each with
a plasmid construct bearing mCherry and measuring the fre-
quency of green to red conversions. The best clone, H9.2Lox.
cre.I, was karyotyped and selected for further studies. When
mCherry was introduced into this clone, a small population of
doxycycline-inducible red fluorescent cells among a large back-
ground of green fluorescent cells was observed, provided cells
had been treated with doxycycline to induce Cre expression just
prior to nucleofection. The measured recombination rate was
Figure 1. Inducible cassette exchange recombination in A2Lox.cre mouse embryonic stem cells (mESCs). (A): The incoming plasmid is shown
above the inducible cassette exchange (ICE) target locus, which is integrated at a unique site in the genome (50 of HPRT in the mESCs). At the
ICE target locus, cre is flanked by heterologous loxP sites and is downstream of a TRE. Arrows indicate recombination between homologous loxP
sites. The heterologous loxP sites on the incoming plasmid are in the opposite orientation relative to their cognates on the chromosome, therefore
recombination catalyzes the integration of the entire plasmid. Cre is exchanged for the incoming gene of interest, rendering that gene doxycycline-
inducible in the derivative recombinants. Selection is enabled by correction of the Dneo gene which acquires a PGK promoter, Kozak translational
consensus and ATG. (B): FACS Fluorescence activated cell sorting analysis of A2Lox.cre ESCs following recombination in the absence of selection.
Cells were either not treated with doxycycline (left) or given a 24-hour pulse of doxycycline (right) prior to nucleofection. After recovery, cells
were reinduced with doxycycline to visualize recombinants. (C): Measured frequency of recombination. n ¼ 3, p < .0049. (D): FACS analysis of a
derivative inducible GFP cell line and control (E14) exposed to doxycycline. Abbreviations: GFP, green fluorescence protein; PGK, phosphoglycer-
ate kinase; TRE, doxycycline (tetracycline)-responsive promoter.
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somewhat lower in hESCs than in mouse cells (Fig. 3B). These
could be sorted and enriched (Fig. 3C). In cells that were not
pretreated with doxycycline to induce Cre expression, nucleofec-
tion with p2Lox-mCherry did not promote the emergence of a
red fluorescent population. We then introduced Myf5 into this
clone on a plasmid bearing an ires-mCherry reporter and isolated
recombinants by flow cytometry. The derivative recombinant
cell line was then differentiated in suspension EB culture for 10
days followed by attachment to gelatin-coated dishes in the pres-
ence of doxycycline. In both Myf5-induced and Myf5-uninduced
cultures, a mesenchymal cell population emerged from the
attached EBs and expanded over the course of 17 days. Medium
was then changed to 2% HS to promote differentiation, and at
this point a clear difference was observed between the control
and induced cultures, with the latter having an abundance of
long spindle-shaped cells. After 1 week in differentiation me-
dium, the Myf5-induced cultures displayed a substantial amount
of cell fusion, and multinucleated cells were positive for sarco-
meric myosin (Fig. 3E). Analysis of gene expression further
indicated myogenic differentiation: as seen with the mESC cul-
tures exposed to Myf5, the downstream myogenic regulatory fac-
tors (MRFs), MyoD and Myogenin, as well as the differentiation
marker, Desmin were now coexpressed (Fig. 3F). Markers of
myogenic differentiation were also shown by Western blotting
(Fig. 3G). These genes were not induced in the control cultures.
This efficient and conditional skeletal myogenic differentiation
highlights the utility of ICE in hESCs to manipulate genetic
pathways controlling lineage specification during differentiation
in vitro.
ICE Recombination in Primary Cells In Vitro
Many applications directed toward probing the stability of
cell fate and the feasibility of reprogramming would be facili-
tated by isogenic methods to compare conditional gene
Figure 2. Modification of ICE mouse ESC (mESC) with Myf5, and efficient myogenesis in vitro. (A): Schematic overview of mouse myogenic
differentiation protocol. (B): Immunostaining for MyoD or sarcomeric myosin heavy chain (MyHC) in progeny of iMyf5 mESCs or control pa-
rental A2Lox.cre mESCs at the final stage of differentiation (in 2% horse serum) in the presence or absence of doxycycline. (C): Myogenic gene
expression measured by quantitative reverse transcriptase PCR (RT-PCR) in the same cells. (D): Myogenic protein expression measured by West-
ern blotting in the same cells. Abbreviations: ESC, embryonic stem cell; EB, embryonic body; DAPI, 40,6-diamidino-2-phenylindole; MCK, mus-
cle creatine kinase; MyHC, myosin heavy chain.
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expression in primary cells. However, making multiple modi-
fications of ESCs and taking each cell line through the blasto-
cyst into the germ line to derive new strains would be practi-
cal only for a very limited number of constructs. On the other
hand, a large number of isogenic modifications could be gen-
erated in primary cells from an animal bearing an ICE locus.
We therefore derived an ICE mouse strain through blastocyst
injection of A2Lox.cre ESCs and tested the efficiency of
recombination in primary cells of these mice. In primary cells
derived from the kidneys of ICE mice, the recombination
rate, measured by acquisition of doxycycline-inducible
DsRED2 protein, was observed to be slightly over 1 in 104
cells (Fig. 4B). We then integrated Myf5 and selected a popu-
lation of G418-resistant cells. Primary cells from the kidney
are not myogenic, do not express MyoD, and will not fuse
under conditions of growth factor withdrawal (Fig. 4D, con-
trol). However, after 1 week of exposure to Myf5, myogenic
potential was acquired by these cells, indicated by nuclear
staining for MyoD, and the ability to fuse to form MyHC-pos-
itive myotubes in conventional myoblast differentiation
Figure 3. Inducible cassette exchange recombination in H9 hESCs and efficient myogenesis in vitro. (A): Schematic of the ICE locus, modified
to include an ires-GFP reporter gene. (B): Fluorescence activated cell sorting (FACS) analysis of doxycycline-induced H9.2Lox.cre.I ESCs (left
panel) and control uninduced H9.2Lox.cre.I cells (right panel) after nucleofection with p2Lox-DsRed2. Inducible red fluorescence replaces inducible
green fluorescence in the recombinants. Quantification over several replicate experiments is shown at right. (C): Fluorescent red cells were sorted
and enriched. (D): Scheme of human myogenic differentiation. (E): Immunofluorescence for sarcomeric MyHC in H9.iMyf5 cells differentiated in
the absence (above) or presence (below) of doxycycline. (F): Myogenic gene expression measured by quantitative RT-PCR in the same cells. (G):
Myogenic protein expression measured by Western blotting in the same cells. BF, bright field; DAPI, 40,6-diamidino-2-phenylindole; EB, embryonic
body; GADPH, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; hECS, human embryonic stem cells; MyHC, myosin
heavy chain; TRE, doxycycline (tetracycline)-responsive promoter.
Iacovino, Bosnakovski, Fey et al. 1585
www.StemCells.com
medium (Fig. 4D, doxycycline). Transcriptional and protein
analysis of skeletal muscle-specific markers including MyoD,
Myogenin, MCK (muscle creatine kinase), Desmin, and
M-cadherin, (Fig. 4E, 4F) further validate the transdetermina-
tion of these kidney-derived cells into the skeletal myogenic
lineage on induction of Myf-5.
Figure 4. Inducible cassette exchange (ICE) mice and respecification of cell fate in primary cells. (A): Schematic overview of recombination in
ICE mice: primary cells are expanded and transfected with p2Lox. Recombinants (indicated in dark beige) are selected with G418 and expanded.
When doxycycline is applied, the gene brought in on p2Lox (DsRed2 in the examples shown in (B) and (C), below) is induced. (B): Recombina-
tion in primary kidney cells nucleofected with p2Lox-DsRed2. Controls were not pretreated with doxycycline to induce cre expression prior to
nucleofection. After nucleofection, cells were allowed to recover and expand in the absence of doxycycline and were later treated with 500
ng/mL doxycycline to visualize recombinants. The histogram at right indicates the average recombination rate over n ¼ 3 independent experi-
ments. p ¼ .0161. (C): Fluorescence activated cell sorting (FACS) for DsRed2 in the cells shown in (B) after growing out in 150 lg/mL G418.
(D): Immunohistochemistry for MyoD and MyHC in Myf5-recombinant kidney cells cultured in 2% horse serum. (E): Gene expression analysis
by quantitative reverse transcriptase (RT)-PCR for skeletal myogenic markers. (F): Myogenic protein expression measured by Western Blotting
in the same cells. Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; GADPH, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluores-
cent protein; MCK, muscle creatine kinase; MyHC, myosin heavy chain.
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DISCUSSION
The ICE recombination system is versatile—easily set up in any
cellular model system, robust—a cre expression plasmid is not
required, cre is expressed at the same level by every cell prior to
recombination, and the reaction is self-limiting because after
recombination cre is gone (indeed, recombination occurs at levels
two or three orders of magnitude above conventional homologous
recombination), and rapid—a pure population of derivative induci-
ble gene-expressing recombinants can be obtained within a time
frame measured in days. This latter feature is particularly valuable
in cells of limited lifespan, such as primary cells, or cells in which
high passage numbers are undesirable, such as ESCs.
Whether at a known location, such as upstream of HPRT,
or an unknown locus, such as a proviral integration site, all
cre-mediated integrations into a given cell type are targeted
to the same locus. This reduces variation in expression associ-
ated with integration site and copy number differences and
eliminates the likelihood that unwanted genetic changes, such
as activation of oncogenes, will occur. These features allow
elements of an allelic series, for example, a set of different
point mutations or deletions within a protein, to be compared
to one another directly and phenotypes to be interpreted with
confidence.
The conditional doxycycline-inducible nature of the target
locus is well suited to gain-of-function experiments. Here, we
have focused on determining the effect of a particular tran-
scription factor on the selection of differentiation pathways,
or on the acquisition of a novel differentiation pathway. In
both the murine and the human system, expression of Myf5
in early mesodermal progenitor cells is an efficient way of
promoting the skeletal myogenic lineage. This lineage is par-
ticularly difficult to derive from both mESCs and hESCs—
although a few examples of skeletal myogenic differentiation
of wild-type ESCs or iPSCs have been reported, these involve
complex protocols based on sorting of rare cells [27, 28]. For
studies requiring large quantities of early embryonic myo-
genic progenitors, genetic modification with inducible expres-
sion of genes such as Myf5, or its upstream regulators Pax3
and Pax7 [22, 29, 30], are ideal.
Additional applications, for example, the modification of
iPSC lines or the integration of reporter genes at this locus
with minimal position effect are also possible.
CONCLUSION
The ability of ESCs to differentiate into all somatic cell types
and the inherent scalability of cultures initiated with immortal
cells makes this a powerful system in which to combine dis-
covery of cellular or developmental phenotypes with mecha-
nistic investigations of the role of a developmental regulatory
factors.
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